Royalty Pharma Acquires Royalty Interest in Cabozantinib From GSK
Royalty Pharma (RPRX) has acquired royalty interests in Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of $342 million, plus up to $50 million contingent on future regulatory approvals for prostate and lung cancer. Cabometyx is already approved for advanced renal cell carcinoma and hepatocellular carcinoma. In 2020, sales of Cabometyx were $742 million, and Cometriq's sales were €289 million. GSK retains a 3% royalty on worldwide net sales of cabozantinib products, while Royalty Pharma will receive royalties in non-U.S. markets and U.S. royalties through September 2026.
- Acquisition of royalties enhances revenue potential from Cabometyx and Cometriq.
- Cabometyx's broad development program may expand to prostate and lung cancer, increasing market opportunities.
- Strong historical sales: $742 million for Cabometyx and €289 million for Cometriq in 2020.
- GSK retains a 3% royalty on worldwide net sales, limiting future earnings.
- U.S. royalties will revert to GSK after September 2026, creating potential financial strain.
NEW YORK, April 01, 2021 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it has acquired a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline (GSK) for an upfront payment of
Cabometyx, a multi-tyrosine kinase inhibitor (TKI), is approved for the treatment of patients with advanced renal cell carcinoma (RCC) both as monotherapy and in combination with Bristol Myers Squibb’s Opdivo (nivolumab) as a first line treatment. Cabometyx is also approved for hepatocellular carcinoma (HCC) in patients previously treated with sorafenib. Cometriq is approved for progressive, metastatic medullary thyroid cancer. Cabometyx and Cometriq are marketed by Exelixis in the United States, and by their partner Ipsen in regions outside the U.S. and Japan. Cabometyx is marketed in Japan by Exelixis’ partner Takeda.
“We are delighted to acquire this royalty stream from GSK,” said Pablo Legorreta, founder and Chief Executive Officer of Royalty Pharma. “Cabometyx is a leading TKI for the treatment of advanced kidney and liver cancer. The recent U.S. approval for the first line treatment of advanced kidney cancer in combination with Opdivo represents an important advance for patients to improve treatment outcomes and quality of life. We are impressed by the broad development program supporting Cabometyx, which includes additional studies in RCC, HCC and the potential to expand into prostate and lung cancer, as well as the strong global commercial execution.”
GSK is entitled to a
In 2020, sales of Cabometyx and Cometriq reported by Exelixis and Ipsen were
Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty Pharma on the transaction.
About Royalty Pharma plc
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J’s Imbruvica, Astellas and Pfizer’s Xtandi, Biogen’s Tysabri, Gilead’s HIV franchise, Merck’s Januvia, Novartis’ Promacta, and Vertex’s Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma plc’s Forward-Looking Statements
The information set forth herein does not purport to be complete or to contain all of the information you may desire. Statements contained herein are made as of the date of this document unless stated otherwise, and neither the delivery of this document at any time, nor any sale of securities, shall under any circumstances create an implication that the information contained herein is correct as of any time after such date or that information will be updated or revised to reflect information that subsequently becomes available or changes occurring after the date hereof. This document contains statements that constitute “forward-looking statements” as that term is defined in the United States Private Securities Litigation Reform Act of 1995, including statements that express the company’s opinions, expectations, beliefs, plans, objectives, assumptions or projections regarding future events or future results, in contrast with statements that reflect historical facts. Examples include discussion of Royalty Pharma’s strategies, financing plans, growth opportunities and market growth. In some cases, you can identify such forward-looking statements by terminology such as “anticipate,” “intend,” “believe,” “estimate,” “plan,” “seek,” “project,” “expect,” “may,” “will,” “would,” “could” or “should,” the negative of these terms or similar expressions. Forward-looking statements are based on management’s current beliefs and assumptions and on information currently available to the company. However, these forward-looking statements are not a guarantee of Royalty Pharma’s performance, and you should not place undue reliance on such statements. Forward-looking statements are subject to many risks, uncertainties and other variable circumstances, and other factors. Such risks and uncertainties may cause the statements to be inaccurate and readers are cautioned not to place undue reliance on such statements. Many of these risks are outside of Royalty Pharma’s control and could cause its actual results to differ materially from those it thought would occur. The forward-looking statements included in this document are made only as of the date hereof. Royalty Pharma does not undertake, and specifically declines, any obligation to update any such statements or to publicly announce the results of any revisions to any such statements to reflect future events or developments, except as required by law. Certain information contained in this document relates to or is based on studies, publications, surveys and other data obtained from third-party sources and Royalty Pharma’s own internal estimates and research. While Royalty Pharma believes these third-party sources to be reliable as of the date of this document, it has not independently verified, and makes no representation as to the adequacy, fairness, accuracy or completeness of, any information obtained from third-party sources. In addition, all of the market data included in this document involves a number of assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumptions. Finally, while the company believes its own internal research is reliable, such research has not been verified by any independent source. For further information, please reference Royalty Pharma’s reports and documents filed with the U.S. Securities and Exchange Commission (“SEC”) by visiting EDGAR on the SEC’s website at www.sec.gov.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6772
ir@royaltypharma.com
FAQ
What is the significance of Royalty Pharma's acquisition of RPRX's royalty interest from GSK?
What are the financial terms of the Royalty Pharma and GSK deal?
How will the acquisition impact Royalty Pharma's future revenues?
What is the expected revenue from Cabometyx and Cometriq in the near future?
